US Market News
3月前
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued UnderperformanceMarch 17, 2026 9:15 AM
Business Wire
Calls on Company to Reach a Fair Settlement that Appoints Altai Nominees Rishi Bajaj and John Bertrand to the Board
Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317768148/en/
In the letter, Altai calls on the OraSure Board to reach a fair settlement that results in the appointment of Altai’s highly-qualified director nominees, Rishi Bajaj and John Bertrand, to the Board.
Highlights of the letter, which can be found in full here, include:
Chronic Underperformance. OraSure’s share price has dramatically underperformed comparable companies and broader indices over both five- and ten-year periods. Recent underperformance has been driven by repeated operational and strategic failures under the current management team—failures that occurred on the Board’s watch. Despite this track record, the Company continues to burn cash pursuing speculative diagnostics investments to the detriment of shareholders.
A Board Without Skin in the Game. Independent directors collectively own less than 1% of shares outstanding yet collect over $250,000 each per year in compensation. They bear little financial risk for decisions that have destroyed shareholder value. Shareholders who face the very real risk of losing money on their investment deserve a larger voice on the Board.
Pay Without Performance. Over 90% of CEO Carrie Eglinton Manner’s compensation is not tied to share price performance. She has earned an estimated $15 million over her tenure while shareholders have lost 60% of their investment since 2023. Her incentives are plainly misaligned with shareholder interests.
The Imperative for a Strategic Review. OraSure must evaluate a sale of the entire business alongside its current plan. We will represent and advocate for all shareholder interests in this process upon our appointment to the Board to ensure that the outcome delivers the best possible returns to shareholders.
Nominees With a Track Record of Results. Rishi Bajaj led ContextLogic’s transformation from a company burning $80 million of cash per quarter to one that completed a $907.5 million acquisition, producing a share price increase of over 120%. John Bertrand built the company behind the first FDA-cleared autonomous AI diagnostic solution in healthcare. Both nominees will seek to align their compensation directly with shareholder returns.
As previously announced, Altai has formally nominated Rishi Bajaj and John Bertrand for election at the 2026 Annual Meeting of Shareholders.
About Altai Capital Management
Altai Capital Management is a technology-focused investment firm founded in 2009 by Rishi Bajaj. Altai Capital makes long-term investments across a diverse range of financial instruments, including debt, private equity, venture capital, and publicly traded securities. To learn more, visit www.altai.com
Disclaimers
This press release and the opinions herein are for general information only, and are not intended to be, nor should they be construed as, an offer to sell or a solicitation of an offer to buy any security, a recommendation to purchase or sell any security, or legal, financial, tax, investment, or other advice.
Altai Capital Management, L.P., Altai Capital Management, LLC, Altai Capital Osprey, LLC, Rishi Bajaj and John Bertrand (collectively, the “Participants”) intend to file with the SEC a definitive proxy statement and accompanying form of proxy to be used in connection with the solicitation of proxies from the stockholders of OraSure Technologies, Inc. Stockholders are advised to read the definitive proxy statement and other documents related to the solicitation of proxies by the Participants when they become available, as they will contain important information, including additional information related to the Participants. The definitive proxy statement and an accompanying proxy card will be furnished to OraSure Technologies, Inc. stockholders and will be, along with other relevant documents, available at no charge on the SEC website at http://www.sec.gov/.
Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained in Exhibit 1 to the Schedule 14A filed by the Participants with the SEC on March 17, 2026. This document is available free of charge from the source indicated above.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260317768148/en/
Media Contact:
ASC Advisors
Taylor Ingraham / Max Rayden
tingraham@ascadvisors.com / mrayden@ascadvisors.com
Original: Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
whytestocks
6年前
Just In: $OSUR OraSure's OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2
BETHLEHEM, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its DNA Genotek subsidiary has received Emergency Use Auth...
Read the whole news OSUR - OraSure's OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2
HokieHead
6年前
More nice news this AM. This biotech is turning in to a beast. In since $11 area and dollar costing the whole way up for long term portfolio.
OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries
May 12 2020 - 08:00AM GlobeNewswire Inc.
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service.
The unified Diversigen operation will continue to offer the science-driven, customized solutions for metagenomics sequencing, bioinformatics, and statistical analysis for the study of the microbiome for which CoreBiome and Diversigen are known. The unification elevates Diversigen as the cornerstone brand for microbiome services in the industry.
The combined organization includes scientific experts representing more than a century of microbiome experience and over 300 articles in respected scientific publications with more than 100,000 citations.
“The new Diversigen brand reflects the combined strength and innovation of these two microbiome service pioneers and positions the OraSure family of companies as an industry leader in this fast-growing industry. Together they will enable us to expand our services as we work to advance global health and bring our customers the tools, services and data-driven insights they need to get reliable, actionable answers to their most critical scientific and healthcare questions,” said Stephen S. Tang, Ph.D., President and Chief Executive Officer, OraSure Technologies, Inc.
All services previously offered under the CoreBiome brand will continue to be available from Diversigen, offering the microbiome market unparalleled choice in sequencing, bioinformatics and analysis services.
The rebrand was implemented after in-depth research, market analysis, and customer conversations. A new Diversigen logo will bring a sharp new visual identity, representing the best of both CoreBiome and Diversigen and characterizes the brand as smart, market-driven, and innovative.
The new Diversigen website is available at diversigen.com.
HokieHead
6年前
Article today, big things ahead for Orasure. 2021, possibly billions of units, that’s huge revenues..
OraSure President and CEO Stephen Tang said the company began considering developing a test as COVID-19 began spreading in January and February.
The company plans to develop a SARS-CoV-2 that, like its HIV test, will be suitable for home use and can provide results in under an hour, Tang said. He said the company aims to launch the product in September. Tang said that OraSure can currently manufacture about 13 million tests per year.
He noted, however, that some official plans to safely reopen the economy call for a billion tests per year.
"We're going to have to find a way to massively scale up," he said. "We're looking to design massive manufacturing of this from the start. Our job is to find facilities and manufacturers and partners who can jump in quickly to that manufacturing environment."
He said he anticipated being able to reach "full-scale manufacturing sometime in 2021," with a target of "tens of millions to a billion units per year."
https://www.modernhealthcare.com/technology/rapid-antigen-assays-could-prove-key-addressing-sars-cov-2-testing-limitations
HokieHead
6年前
An in-home coronavirus test is being developed in Bethlehem. And the feds are backing it.
Updated Apr 06, 2020; Posted Apr 06, 2020
OraSure Technologies, the Bethlehem-based tech company that gained notoriety years ago with its rapid HIV test, has been awarded a $710,310 federal contract to develop an in-home coronavirus test, the company announced Monday morning.
The contract comes from the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services. It will enable OrasSure to file for special authorization from the FDA allowing the in-home test to debut in the U.S. market.
OraSure is billing the test’s development as a possible breakthrough in the fight against the coronavirus pandemic.
Once its developed and the necessary approvals are obtained, the test would help alleviate the pressure on over-burdened healthcare systems, a news release from OraSure says.
“Healthcare providers, retailers, and online vendors could ship tests directly to an individual’s home, eliminating unnecessary trips to hospitals, doctors’ offices, and testing facilities,” the release says. “This would help maintain social distancing and curb the spread of coronavirus through symptomatic and asymptomatic transmission. Rapid in-home testing could also ease the burden on lab-based testing.”
XenaLives
6年前
Security OSUR / OraSure Technologies, Inc. (68554V108)
President and CEO TANG STEPHEN S PHD
ISIN US68554V1089
Industry Surgical and Medical Instruments and Apparatus
Institutional Owners 401
Institutional Shares 58,419,785 - 94.70%
Common Shares Outstanding 61,687,392 shares (as of 2019-03-31)
Institutional Value $ 1,736,356 USD
https://fintel.io/so/us/osur